Clinical Trials Logo

Leukemia, Myeloid, Chronic-Phase clinical trials

View clinical trials related to Leukemia, Myeloid, Chronic-Phase.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06423911 Not yet recruiting - Clinical trials for Chronic Myeloid Leukemia

A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML

POLARIS-2
Start date: May 2024
Phase: Phase 3
Study type: Interventional

A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)

NCT ID: NCT06409936 Not yet recruiting - Clinical trials for Chronic Myeloid Leukemia

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

PEARL
Start date: September 2024
Phase: Phase 2
Study type: Interventional

A phase 2, interventional, randomized unblinded study will be conducted in newly diagnosed CP CML patients, to investigate the efficacy and the safety of asciminib at a dose of 80 mg QD as single agent (arm A) or 40 mg BID in combination with nilotinib 300 mg BID (arm B). All patients in both arm A and arm B will be treated for a minimum of 2 years (core phase). If they will have achieved a DMR (MR4), or if it will be in the interest of the patient, the treatment will be continued. During the consolidation phase (2 years) asciminib will be continued at the same dose in both arms; in the combination arm the nilotinib dose will be reduced to 300 mg daily. The patients maintaining a stable MR4 up to the end of the fourth year will discontinue the treatment (TFR phase). The rate of TFR at 5 year (1 year after discontinuation) will be evaluated.

NCT ID: NCT06368414 Not yet recruiting - Clinical trials for Chronic Myeloid Leukemia, Chronic Phase

A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia

AsterA
Start date: September 1, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI

NCT ID: NCT06121765 Not yet recruiting - CML, Chronic Phase Clinical Trials

Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI

Start date: November 1, 2023
Phase:
Study type: Observational

Metabolic alternation and clinicohematological characteristic in chronic phase CML in patient treated with TKI

NCT ID: NCT05367765 Not yet recruiting - CML, Chronic Phase Clinical Trials

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Start date: April 30, 2022
Phase: Phase 4
Study type: Interventional

Flumatinib is an orally available TKI with high selectivity and potency against BCR-ABL1 kinase. It's a multi-center, open-label, real world study to explore the efficacy and safety of Flumatinib versus Imatinib as the first line therapy in patients with chronic myleiod leukemia(CML) in chronic phase(CP).

NCT ID: NCT04709731 Not yet recruiting - Clinical trials for Chronic Myeloid Leukemia (CML)

Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia

CarPAs
Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

This study will address the therapeutic activity and the safety/biological profile of Ponatinib when used as third line therapy of Chronic Myeloid Leukemia in Chronic Phase after the only two TKIs known for their cardiovascular safety, i.e. Imatinib and Bosutinib.

NCT ID: NCT03907670 Not yet recruiting - Clinical trials for Chronic Phase Chronic Myelogenous Leukemia

Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor

Start date: October 1, 2019
Phase:
Study type: Observational

The aim of the study is to assesse the levels of various biomarkers, specifically interleukin (IL)-6, platelet-derived microparticles (PDMPs), 11, 12 soluble vascular cell adhesion molecule 1 (sVCAM-1), transforming growth factor (TGF) β1, and sCTLA-4, in TKI-treated patients with CML. To measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML..

NCT ID: NCT02687425 Not yet recruiting - Clinical trials for Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia

SESPI
Start date: February 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficiency of adding pioglitazone to chronic phase chronic myelogenous leukemia patients having received imatinib mesylate who have acquired a stable molecular response but not complete molecular response.